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Abstract 
Background: Patients with severe mental illness (SMI) have a reduced life expectancy of one to two decades as 
compared to the general population, with most years of life lost due to somatic diseases. Most previous studies on 
disorders constituting SMI, e.g. schizophrenia and bipolar disorder, have investigated the disorders separately and 
hence not compared the disorders in terms of mortality rates relative to the background population.
Methods: A register‑based cohort study including the entire Danish population comparing mortality rates relative to 
the background population, controlling for age and sex, i.e. standardized mortality ratios (SMRs) in patients diagnosed 
with schizophrenia with those in patients diagnosed with bipolar disorder, during the study period from 1995 to 2014.
Results: The SMR of patients with SMI was significantly higher than one for each calendar year in the study period 
with an overall SMR of 4.58, 95% CI (4.48–4.69) in patients diagnosed with schizophrenia (n = 38,500) and of 2.57 
(95% CI 2.49–2.65) in patients diagnosed with bipolar disorder (n = 23,092). When investigating time trends in SMR for 
schizophrenia and for bipolar disorder, respectively, an increase in SMR over time was shown with a mean increase of 
0.03 per year for schizophrenia and 0.02 for bipolar disorder (p < 0.01 for both disorders). The ratio between SMR for 
schizophrenia and SMR for bipolar disorder for each calendar year over the study period was constant (p = 0.756).
Conclusions: Increasing SMRs over the last 20 years were found for both patients diagnosed with bipolar disorder 
and patients diagnosed with schizophrenia. Despite clear differences between the two disorders regarding SMRs, the 
increases in SMR over time were similar, which could suggest similar underlying factors influencing mortality rates in 
both disorders.
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Background
Patients diagnosed with bipolar disorder and patients 
diagnosed with schizophrenia, constituting a group 
of patients with severe mental illness (SMI), have a 
reduced life expectancy of one to two decades as com-
pared to the background population (Nordentoft et al. 
2013). There is a large increased relative risk of suicide 
or accidents as the cause of death, but most years of 
life lost are attributable to somatic disorders, similar 
to the findings in the general population (Nordentoft 
et  al. 2013). Specialized treatment interventions have 
been shown to be effective in reducing the psychi-
atric outcomes as relapse and hospitalization (Kess-
ing et al. 2013; Correll et al. 2018), but so far outcome 
data on mortality and somatic morbidity have not been 
reported. Patients with severe mental illness have an 
increased rate of poor life style such as lack of exer-
cise, poor diet, increased occurrence of smoking and 
obesity, resulting in increased rates of chronic somatic 
diseases leading to excess mortality rates (Mitchell 
et  al. 2015; Vancampfort et  al. 2015, 2016, 2017). In a 
recent study by Speyer et  al. no effect of care coordi-
nation and lifestyle coaching was seen on the primary 
outcome of 10-year risk of cardiovascular disease when 
compared to treatment as usual (Speyer et al. 2016). In 
the study by Kugathasan et  al. investigating long-term 
outcome after myocardial infarction in patients with 
schizophrenia, no difference in short-term outcome 
compared to patients experiencing myocardial infarc-
tion but not diagnosed with schizophrenia was shown, 
whereas an increased long term mortality was reported 
(Kugathasan et  al. 2018). The study by Jakobsen et  al. 
showed similar results and showed furthermore no dif-
ference in the in-hospital treatment between patients 
with SMI and the background population, whereas a 
lower percentage of patients with SMI received the rec-
ommended medical treatment during follow-up result-
ing in an increased risk of new adverse cardiac events 
(Jakobsen et al. 2017).
Most studies have reported life expectancy or mortality 
rates for psychiatric disorders separately and not investi-
gated the mortality for several disorders to compare the 
disorders with each other. Several studies have shown an 
increasing mortality gap between patients diagnosed with 
schizophrenia, patients diagnosed with bipolar disorders 
and comparative non-psychiatric populations (Nielsen 
et al. 2013; Hayes et al. 2017). We have previously studied 
the time trends of standardized mortality ratios (SMRs), 
i.e. mortality relative to the background population con-
trolling for age and gender, in patients diagnosed with 
bipolar disorder over the last 20  years (Staudt Hansen 
et al. 2018). In the current study, we aimed at investigat-
ing SMRs for each single year from 1995 to and including 
2014 for both schizophrenia and bipolar disorder. Fur-
thermore, we aimed at comparing the two disorders 
regarding time trends in the SMRs over the study period.
Methods
Design
A register-based cohort study including the entire Danish 
population.
Study population
All patients registered with a schizophrenia or bipo-
lar disorder diagnosis in the Danish Psychiatric Cen-
tral Research Registry (DPCRR) from 1965 until the 
end of 2014, living in Denmark, alive and below the age 
of 65 years in the study period from 1995 to 2014 were 
defined as the severe mental illness population and 
included in the current study.
Included patients reaching the age of 65  years during 
the study period were censored at that time point. Schiz-
ophrenia was defined as an ICD-8 300.x diagnosis in the 
period 1965 to end of 1994 or and ICD-10 F20.x diagno-
sis in the period 1995 to end of 2014. Bipolar disorder 
was defined as an ICD-8 296.x diagnosis in the DPCRR 
in the period 1965 to the end of 1994 or an ICD-10 F30.x 
or F31.x diagnosis in the period 1995 to the end of 2014, 
resulting in the inclusion of both incident and prevalent 
cases in contact with hospital-based in- or out-patient 
treatment facilities. If patients were diagnosed with both 
bipolar disorder and schizophrenia, patients were ana-
lyzed according to the schizophrenia diagnosis.
Registers utilized
Data on psychiatric contacts were retrieved from the 
DPCRR (Mors et  al. 2011) and the Danish National 
Patient Register (Lynge et al. 2011).
Data on date of deaths of patients and background pop-
ulation were retrieved from the Danish Civil Registration 
System (Pedersen 2011).
All inhabitants of Denmark have a unique person iden-
tification number—civil person registration number 
(CPR)—that enables linkage between registers.
Statistical analyses
The standardized mortality ratio (SMR) for the whole 
study period was calculated separately for patients diag-
nosed with schizophrenia and for patients diagnosed 
with bipolar disorder as the observed number of deaths 
among patients with either schizophrenia or bipolar dis-
order divided by the expected number of deaths based on 
the age and gender specific mortality rates of the general 
population (Naing 2000). Secondly, time trends of SMR 
during the 20-year follow-up period were assessed using 
random effects linear regression, with SE as random 
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effect (Juliouset al. 2001), setting the significance level of 
the p value of the slope < 0.05, for each of the two diag-
nostic groups. Lastly, time trends of ratios of annual SMR 
for schizophrenia to annual SMR for bipolar disorder 
during the 20-year follow-up period were assessed using 
random effects linear regression, with SE as random 
effect (Julious et al. 2001), setting the significance level of 
the p-value of the slope < 0.05.
Data management and statistical analyses were per-
formed in Stata 15 (StataCorp, College Station, TX, 
USA).
Results
The total population consisted of 6,176,414 persons with 
38,500 patients (23,625 male and 14,875 female) with 
a schizophrenia diagnosis and 23,092 (9510 male and 
13,582 female) patients with a bipolar disorder diagnosis 
alive in the period 1995 to 2014.
The SMR of patients with SMI was significantly higher 
than one for each calendar year in the study period 
(Table 1), with an overall SMR of 4.58, 95% CI (4.48–4.69) 
in patients diagnosed with schizophrenia and 2.57 (95% 
CI 2.49–2.65) in patients diagnosed with bipolar disorder 
for the whole study period.
When investigating time trends in SMRs for schizo-
phrenia and bipolar disorder respectively an increase 
in SMR over time was shown with a mean increase of 
0.03, p < 0.01, in SMR per year in patients diagnosed 
with schizophrenia and 0.02, p < 0.01, in SMR per year 
in patients diagnosed with bipolar disorder, as shown in 
Fig. 1.
The ratio between annual SMRs for schizophrenia over 
the study period and annual SMRs for bipolar disor-
der over the study period was unchanged over the study 
period (p = 0.7560), as shown in Fig. 2.
Discussion
In this nationwide study including more than 65,000 
patients diagnosed with SMI below the age of 65, the 
overall mortality rate was more than four times higher 
for patients diagnosed with schizophrenia and more 
than two-and-a-half times higher for patients diagnosed 
with bipolar disorder than that of the general popula-
tion, standardized for age and gender. Furthermore, the 
increase in annual SMRs over the study period was simi-
lar in the two groups diagnosed with SMI. Accordingly, 
the ratio between the annual SMRs for the two psychiat-
ric populations was unchanged over time.
Table 1 Standardized mortality ratios in  the  study period for  patients diagnosed with  schizophrenia and  patients 
diagnosed bipolar disorder, respectively
Obs deaths observed number of deaths, Exp deaths expected number of deaths, SMR standardized mortality ratio, CI confidence interval
Year Schizophrenia Bipolar disorder
Obs deaths Exp deaths SMR 95% CI Obs deaths Exp deaths SMR 95% CI
1995 278 67.25 4.13 3.68 4.65 279 121.60 2.29 2.04 2.58
1996 265 68.95 3.84 3.41 4.34 299 115.51 2.59 2.31 2.90
1997 303 70.52 4.30 3.84 4.81 253 108.64 2.33 2.06 2.63
1998 309 71.51 4.32 3.86 4.83 243 104.42 2.33 2.05 2.64
1999 348 74.31 4.68 4.22 5.20 250 102.31 2.44 2.16 2.77
2000 316 75.20 4.20 3.76 4.69 212 97.53 2.17 1.90 2.49
2001 357 78.25 4.56 4.11 5.06 238 94.60 2.52 2.22 2.86
2002 370 81.58 4.54 4.10 5.02 252 91.85 2.74 2.42 3.10
2003 400 84.71 4.72 4.28 5.21 248 89.62 2.77 2.44 3.13
2004 409 86.25 4.74 4.30 5.22 241 87.22 2.76 2.44 3.14
2005 433 84.30 5.14 4.67 5.64 201 82.94 2.42 2.11 2.78
2006 428 89.40 4.79 4.35 5.26 236 84.30 2.80 2.46 3.18
2007 447 93.32 4.79 4.37 5.26 222 84.95 2.61 2.29 2.98
2008 408 90.16 4.53 4.11 4.99 245 79.95 3.06 2.70 3.47
2009 417 92.10 4.53 4.11 4.98 196 78.44 2.50 2.17 2.87
2010 419 92.46 4.53 4.12 4.99 195 75.31 2.59 2.25 2.98
2011 412 88.06 4.68 4.25 5.15 195 69.74 2.80 2.43 3.22
2012 410 86.48 4.74 4.30 5.22 176 66.87 2.63 2.27 3.05
2013 397 85.74 4.63 4.20 5.11 174 64.81 2.68 2.31 3.11
2014 419 85.37 4.91 4.46 5.40 180 64.07 2.81 2.43 3.25
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Fig. 1 Standardized mortality ratios including 95% confidence intervals for patients diagnosed with schizophrenia (yellow points) and bipolar 
disorder (green points) compared to the general Danish population from 1995 to 2014. The dotted lines are fitted utilizing linear regression
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Fig. 2 Ratio of standardized mortality ratio for schizophrenia divided by standardized mortality ratio for bipolar disorder. The dotted line is fitted 
utilizing linear regression
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Similar to our findings, previous studies have shown 
increases in the relative mortality gap over time between 
the patients diagnosed with schizophrenia and bipolar 
disorder respectively and background populations (Hayes 
et  al. 2015; Lee et  al. 2018). Hayes et  al. (2017) showed 
an increased mortality rate in both patients diagnosed 
with schizophrenia as well as in patients diagnosed 
with bipolar disorder, but did not find a two-fold differ-
ence in relative mortality rates as compared to the back-
ground population. Contrary to the currents study, Hayes 
et al. (2017) utilized several regression models to inves-
tigate time trends in mortality rates as well as to adjust 
to explanatory variables. Lastly, the study by Hayes et al. 
(2017) supported a general decrease in absolute mor-
tality rates for all investigated, but a larger reduction in 
absolute mortality rates for the background population, 
resulting in an increasing mortality gap between patients 
diagnosed with bipolar disorder or schizophrenia as 
compared to the background population. Studies have 
also shown a general lowered life expectancy in patients 
diagnosed with SMI (Nordentoft et  al. 2013), which 
might have been caused by poorer treatment of physi-
cal diseases (Laursen and Nordentoft 2011; Laursen et al. 
2013; Kugathasan et  al. 2018) and by higher prevalence 
of physical co-morbidities and more unhealthy lifestyle 
in patients with SMI as compared to the background 
population (Mitchell et al. 2015; Vancampfort et al. 2015, 
2016, 2017). Poor lifestyle choices like low physical activ-
ity (Vancampfort et  al. 2017), poor diet (Teasdale et  al. 
2017), and lack of smoking cessation (Mitchell et  al. 
2015) are still more prevalent in patients with SMI as 
compared to the general population. Also, cardiovascular 
risk factors, diabetes, dyslipidemia and obesity are more 
prevalent in patients with psychiatric disorders than in 
the background population, and the associations of these 
risk factors to psychiatric disorders are not significantly 
changed by treatment with antidepressants or antipsy-
chotics, and these treatments themselves are associated 
to risk factors as well (Pérez-Piñar et  al. 2016). Studies 
investigating the effects of life style interventions have 
been conducted, but have mainly shown disappointing 
results with lack of changes in risk profiles (Speyer et al. 
2016; Ashdown-Franks et al. 2018).
Studies have raised concern regarding disparity in 
treatment of physical disease for patients with SMI, with 
a relatively low quality of care for patients with psychiat-
ric diagnoses in general (Mitchell et al. 2014). In patients 
with SMI and also diagnosed with AIDS, a lowered com-
pliance to medication was observed (Moore et al. 2012), 
and in patients with non-affective psychotic disorders a 
lowered prevalence of prescribed somatic medication 
and fewer consultations with a general practitioner has 
been observed (Swildens et al. 2016), in patients with SMI 
disparities in screening for cancer were observed as well 
as a higher rate of case-fatality, which was not reduced by 
adjusting for cancer stage and comorbidity (Howard et al. 
2010; Manderbacka et al. 2017). In patients with SMI, a 
lowered rate of invasive cardiac procedures was observed 
as compared to the background population despite 
patients being admitted to hospital (Laursen et al. 2009). 
After treatment of somatic disorders an increased risk of 
early rehospitalization in patients with SMI was observed 
for cardiovascular, pulmonary, endocrinological and 
infectious diseases (Davydow et  al. 2016), suggesting an 
unmet need for treatment or a poorer treatment response 
as compared to the background population. Patients with 
SMIs have a well-documented increased rate of mortal-
ity mainly as a consequence of somatic illnesses, even 
when adjusting for stage of illness (Laursen 2011; Wahl-
beck et  al. 2011). In accordance with these findings, a 
decreased proportion of patients with severe mental dis-
orders were screened for breast cancer, cervical cancer or 
general somatic illness as compared to the background 
population (James et al. 2017; Thomas et al. 2018).
Data support a lack of knowledge of mental disorders 
as well as a more negative attitude towards patients with 
mental disorders in nursing staff in somatic care, as com-
pared to nursing staff in mental health (Björkman et  al. 
2008). These negative attitudes, as well as the lack of inte-
gration between somatic and psychiatric treatment cent-
ers might result in the disparity in treatment of somatic 
disorders in patients with SMI, partially influencing mor-
tality, and resulting in patients with SMI not gaining the 
same effects of reduced mortality as a result of improved 
treatment for somatic disease as the background popula-
tion (Fleischhacker et al. 2008).
Our findings suggest that for schizophrenia and bipo-
lar disorder there is a similar increase in mortality gap 
between the two disorders respectively and the back-
ground population. However, by utilizing SMRs as an 
outcome measure, which reports the relative mortality 
rates between a specified population and the background 
population, we were unable to confer if the increasing 
mortality ratio is a result of patients with SMI having an 
increased mortality rate absolutely over time or merely 
a less lowered mortality rate as compared to the back-
ground population. The similar time trends in SMR for 
patients diagnosed with schizophrenia and bipolar disor-
der could suggest similar underlying factors influencing 
mortality, although the design and model of analysis do 
not allow conclusions regarding causality.
Strengths and limitations
In the current study, inclusion of both incident and 
prevalent cases was chosen to increase clinical rel-
evance and generalizability of the results. Nationwide 
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population-based register studies in Denmark benefit 
from several factors. First, reporting data to the Dan-
ish health care registers is mandatory for all in- or out-
patients treated in a hospital-based service treatment. 
As a result, almost no patients are lost to follow-up. Sec-
ondly, in Denmark health care is without any direct cost 
for the individual, as healthcare is provided and paid as 
part of the Danish tax system. Consequently, results 
from Danish studies are not confined to patients with a 
certain socioeconomic status or patients from specific 
geographical regions of a larger country as some health 
insurance database studies might be. The schizophrenia 
diagnosis has been validated in the Danish healthcare 
registers (Uggerby et  al. 2013), and generally the valid-
ity of psychiatric diagnoses is believed to be high (Mors 
et al. 2011), although no specific validation of the bipolar 
disorder diagnosis has been conducted. Due to the very 
long inclusion period, patients were included based on 
the ICD-8 (first part of the period) and on the ICD-10 
(last part of the period). However, those patients diag-
nosed utilizing ICD-8 criteria might not have constituted 
the exact same patient group as those being diagnosed 
according to ICD-10.
The primary outcome of SMR carries some limita-
tions. SMR is only adjusted for age and sex, resulting in 
lack of adjustment for other possible confounders. Uti-
lizing other models would have allowed adjustment for 
more variables, which though could have obscured the 
overall effect of, e.g. life style and socio-economic status, 
which is systematically different in patients with SMI as 
compared to the background population. With the cur-
rent model used, the true excess mortality of this disad-
vantaged patient group is reported. The current findings 
could be biased by including only patients assigned a 
register diagnosis. Thus, persons fulfilling criteria for 
schizophrenia or bipolar disorder, but not diagnosed in 
a psychiatric setting before death, could have biased the 
results conservatively.
Conclusion
Increasing SMRs over the last 20  years were found 
for both patients diagnosed with bipolar disorder and 
patients diagnosed with schizophrenia. Despite clear dif-
ferences between the two disorders regarding SMRs, the 
increases in SMR over time were similar, which could 
suggest similar underlying factors influencing mortality 
rates in both disorders.
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